Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00654238 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | completed | Phase 2 | 59 | University of PennsylvaniaOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT02657369 | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | terminated | Phase 2 | 34 | Eisai Inc.INDUSTRY | 5 | Oct 15, 2019 | clinicaltrials |
| NCT02062632 |
| Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy |
| terminated |
| Phase 2 |
| 5 |
| Mayo ClinicOTHER |
| 1 |
| Oct 1, 2019 |
| clinicaltrials |
| NCT02289144 | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | withdrawn | Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02586350 | Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) | completed | Phase 2 / Phase 3 | 91 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 21, 2019 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00923247 | A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | terminated | Phase 1 / Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00126568 | Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03387943 | PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 3, 2018 | clinicaltrials |
| NCT02114658 | Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients | completed | Phase 2 | 18 | BayerINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01240590 | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT01625520 | SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer | completed | Phase 2 | 19 | Federico II UniversityOTHER | 1 | Apr 25, 2016 | clinicaltrials |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00507429 | Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer(FACT) | terminated | Phase 2 / Phase 3 | 80 | Mateon TherapeuticsINDUSTRY | 12 | Jun 9, 2014 | clinicaltrials |
| NCT00098813 | Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095693 | Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2014 | clinicaltrials |
| NCT01736878 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma(SUMMIT) | withdrawn | Phase 2 | 0 | Eanm Research LtdNETWORK | 1 | May 17, 2013 | clinicaltrials |
| NCT00251316 | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer | completed | Phase 2 | 34 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Feb 4, 2013 | clinicaltrials |
| NCT01739634 | The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer | unknown | Phase 1 / Phase 2 | 10 | Salient Pharmaceuticals IncorporatedINDUSTRY | 1 | Dec 3, 2012 | clinicaltrials |
| NCT00647140 | Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer(DOPMET) | terminated | Phase 2 | 29 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 7, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Nov 18, 2019source: clinicaltrials